CY-219 CAR-T
IIT2025149
Phase 1 small_molecule active
Quick answer
CY-219 CAR-T for Relapsed/Refractory B-cell Lymphoma is a Phase 1 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Relapsed/Refractory B-cell Lymphoma
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active